Komal Kumar Javarappa

Author

Also Known As

Komal Javarappa, Komal K. Javarappa, Komal Kumar Javarappa, KomalKumar Javarappa

Publications

481

Citations

H-Index

Concepts

All Affiliations

Komal Kumar Javarappa is an author at University of Helsinki specializing in immunology, cancer research, and medicine.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	87
2	Immunology	2	2	87
3	Health Sciences	1	1	27
4	Cell Biology	1	1	60
5	Medical Laboratory Science	1	1	27

Komal Kumar Javarappa

Publications

449

Citations

H-Index

Page 1

	Year	Citations
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML Riikka Karjalainen, Tea Pemovska, Mihaela Popa, Blood	2017	120
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia Heikki Kuusanmäki, Olli Dufva, Markus Vähä‐Koskela, Blood	2022	112
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets Shady Adnan Awad, Daehong Kim, Helena Hohtari, Leukemia	2020	71
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia Jarno Kivioja, Angeliki Thanasopoulou, Ashwini Kumar, Leukemia Hematological MalignancyMedicineMalignant Blood DisorderImmunologyNavitoclax Act	2018	60
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations Aleksandr Ianevski, Jenni Lahtela, Komal Kumar Javarappa, Science Advances	2021	49
A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow Komal Kumar Javarappa, Dimitrios Tsallos, Caroline A. Heckman SLAS DISCOVERY ImmunologyPathologyMyeloid NeoplasiaHematological MalignancyBone Marrow Failure	2018	27
Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia Olli Dufva, Heikki Kuusanmäki, Markus Vähä‐Koskela, Blood	2022	10

Page 1